= 0.049), reflecting the burden of neurodegeneration. Our findings demonstrate that breath metabolomics represents a noninvasive, rapid, and scalable approach with substantial clinical potential for PD screening and disease monitoring. The eMS system provides a promising strategy to support early PD diagnosis and dynamic monitoring of disease progression.
Xian et al. (Sun,) studied this question.